Literature DB >> 22362861

Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.

Vincent Cottin1, Sergio Harari, Marc Humbert, Hervé Mal, Peter Dorfmüller, Xavier Jaïs, Martine Reynaud-Gaubert, Grégoire Prevot, Romain Lazor, Camille Taillé, Jacques Lacronique, Sabrina Zeghmar, Gérald Simonneau, Jean-François Cordier.   

Abstract

This retrospective, multicentre study evaluated patients with lymphangioleiomyomatosis (LAM) and pre-capillary pulmonary hypertension (PH) by right heart catheterisation. It was conducted in 20 females with a mean ± SD age of 49 ± 12 yrs and a mean ± SD time interval between LAM and PH diagnoses of 9.2 ± 9.8 yrs. All, except for one patient, were receiving supplemental oxygen. 6-min walking distance was mean ± SD 340 ± 84 m. Haemodynamic characteristics were: mean pulmonary artery pressure (PAP) 32 ± 6 mmHg, cardiac index 3.5 ± 1.1 L · min(-1) · m(-2) and pulmonary vascular resistance (PVR) 376 ± 184 dyn · s · cm(-5). Mean PAP was >35 mmHg in only 20% of cases. The forced expiratory volume in 1 s was 42 ± 25%, carbon monoxide transfer factor was 29 ± 13%, and arterial oxygen tension (P(a,O(2))) was 7.4 ± 1.3 kPa in room air. Mean PAP and PVR did not correlate with P(a,O(2)). In six patients who received oral pulmonary arterial hypertension (PAH) therapy, the PAP decreased from 33 ± 9 mmHg to 24 ± 10 mmHg and the PVR decreased from 481 ± 188 dyn · s · cm(-5) to 280 ± 79 dyn · s · cm(-5). The overall probability of survival was 94% at 2 yrs. Pre-capillary PH of mild haemodynamic severity may occur in patients with LAM, even with mild pulmonary function impairment. PAH therapy might improve the haemodynamics in PH associated with LAM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362861     DOI: 10.1183/09031936.00093111

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

1.  Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Authors:  Andrew M Courtwright; Bruno G Baldi; Pranav Kidambi; Ye Cui; Anthony M Lamattina; Julian A Villalba; Shefali Bagwe; Hilary J Goldberg; Ivan O Rosas; Elizabeth Petri Henske; Carlos R R Carvalho; Souheil El-Chemaly
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 2.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

Review 3.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 4.  Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Authors:  Fatima A Ballout; Ahmad S Manshad; Tochukwu M Okwuosa
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

Review 5.  mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

Authors:  Elena A Goncharova
Journal:  FASEB J       Date:  2013-01-25       Impact factor: 5.191

6.  Multiple pulmonary artery aneurysms in tuberous sclerosis complex.

Authors:  Vincent Dunet; Salah Dine Qanadli; Romain Lazor; Catherine Beigelman-Aubry
Journal:  BMJ Case Rep       Date:  2013-01-21

7.  Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis.

Authors:  Wei Hua; Wenbo Yang; Jianing Gu; Jialiang Wu; Wei Wang; Yanpu Liu; Hong Zhu; Min Zhou; Jieming Qu; Yuehua Fang
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-14       Impact factor: 2.357

Review 8.  Pulmonary arterial hypertension.

Authors:  David Montani; Sven Günther; Peter Dorfmüller; Frédéric Perros; Barbara Girerd; Gilles Garcia; Xavier Jaïs; Laurent Savale; Elise Artaud-Macari; Laura C Price; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Orphanet J Rare Dis       Date:  2013-07-06       Impact factor: 4.123

9.  Management of Pulmonary Hypertension Due to Chronic Lung Disease.

Authors:  Jordan Sugarman; Jason Weatherald
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01

10.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.